Switching to E-Cigarettes and Heated Tobacco Products Reduces Vascular Damage and Smoking-Related Illnesses: Study

Aug.16.2022
Switching to E-Cigarettes and Heated Tobacco Products Reduces Vascular Damage and Smoking-Related Illnesses: Study
CoEHAR researchers found using e-cigarettes and heated tobacco products can reduce smoking-related diseases. Their study challenges misconceptions about vaping.

Researchers from the Center of Excellence for the Acceleration of Harm Reduction (CoEHAR) involved in the Replica project have discovered that switching to electronic cigarettes and heated tobacco products can reduce the incidence of vascular damage and smoking-related diseases. The findings challenge the prevailing misconception that using e-cigarettes and heated tobacco products is just as harmful as smoking.


The study has been published by an independent laboratory affiliated with the Replica Project, whose scientists are world leaders in harm reduction. The latest research assessed the damage caused to endothelial cells, which release substances that control the dilation and contraction of blood vessels, by cigarette smoke compared to electronic cigarettes and heated tobacco products.


Damage to the inner lining of blood vessels known as endothelial damage is a primary pathology that leads to diseases such as atherosclerosis, with smoking being the main culprit. Smoking can impair the normal function of the endothelium, cause damage to the vascular system, and lead to the development of high blood pressure and atherosclerosis. Smoking and exposure to smoke toxins are related to the impairment of the repair mechanism needed for endothelial homeostasis, such as the inhibition of endothelial cell migration.


Reducing exposure to smoke toxins may mitigate the harmful effects on endothelial and cardiovascular disease development. Numerous international studies have investigated the impact of smoking on endothelial cell migration and associated vascular damage, particularly a study by Taylor et al. (2017). Compared to cigarette smoke, exposure to electronic cigarette aerosol significantly reduces inhibition of in vitro (in a test tube) endothelial cell migration. This means that endothelial cells exposed to electronic cigarette aerosol retain their ability to effectively heal small wounds in blood vessels, unlike those exposed to cigarette smoke and toxins, which severely limit their wound repair capacity.


One of CoEHAR's most successful projects is the Replica project, in which researchers have replicated some of the most significant international studies in the field of reducing tobacco harm via an independent laboratory network. They have demonstrated a reduction in the toxicity of electronic cigarettes and have established reference standards for scientific research. The goal of CoEHAR's scientists is to conduct a multicenter replication study to validate the results of Taylor and his colleagues.


A study titled "Comparative evaluation of e-cigarette aerosol and cigarette smoke on endothelial cell migration: a replication study" compared the effects of three commercial e-cigarette delivery systems and traditional cigarettes. Following international scientific standards and utilizing the latest technology and tools, the data collected by researchers at CoEHAR confirmed the findings of Taylor and colleagues: e-cigarettes do not induce inhibition of endothelial cell migration in vitro compared to cigarette smoke, thus reducing harm caused by tobacco smoke. Furthermore, CoEHAR researchers compared the results of two different heated tobacco products, which demonstrated significantly less impact than observed with cigarette smoke.


According to Professor Massimo Caruso, co-project leader of the Replica initiative, "As previously demonstrated by the Replica research team, the harm caused by electronic nicotine delivery systems is significantly lower than the harm caused by cigarette smoke. An interesting fact is that using non-combustible products can reduce vascular damage and prevent the likelihood of smoking-related diseases such as atherosclerosis and hypertension. Our research once again challenges the notion that electronic cigarettes or heated tobacco will cause similar damage to combustible cigarettes.


Statement:


This article is compiled from third-party information and is only meant for industry-related communication and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness and accuracy of its content. The translation of this article is only intended for industry exchange and research.


Due to limitations in the translation process, the translated article may not fully reflect the original expression. Therefore, please refer to the original article for accuracy.


2FIRSTS is fully aligned with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.


The compilation of information is subject to the copyright ownership of the original media outlet and author. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Philip Morris International has published its first report aligned with the Taskforce on Nature-related Financial Disclosures, bringing its electronics supply chain and the use and end-of-life stages of smoke-free devices and consumables into its nature-related assessment. PMI said its smoke-free business accounted for about 42% of total net revenues in the second quarter of 2026. The report says non-circular electronic products, particularly single-use items, can increase consumption of limited natural resources and also details an IQOS repair pilot. A 2040 circularity scenario tests assumptions including a 50% reduction in product waste-related costs, 10% raw-material savings and a 25% substitution rate for refurbished products versus new products.
Sep.23
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
Global Nicotine-Pouch E-Commerce Group Haypp Shuts Sweden’s Snusnetto Over Age Verification as Identity Checks Become Industry Infrastructure for New Nicotine Products
Global Nicotine-Pouch E-Commerce Group Haypp Shuts Sweden’s Snusnetto Over Age Verification as Identity Checks Become Industry Infrastructure for New Nicotine Products
Sweden's Supreme Administrative Court has declined to hear an appeal over age verification for tobacco and nicotine products collected from parcel lockers, leaving in place a lower-court ruling that geo-located BankID verification is insufficient to securely verify the actual recipient. Haypp Group has stopped tobacco and nicotine sales through Snusnetto and is deploying a new system across its other Swedish e-commerce sites to verify the age of the person who actually opens the locker and receives the shipment. The change comes as age verification across next-generation nicotine products expands from purchase checks into retail, delivery and, for some e-cigarettes, device access itself.
Regulations
Oct.20
South Korea's Tobacco Plan Excludes 6-Methyl Nicotine as Customs Tightens Import Controls and Analog Liquid Imports Fall 83%
South Korea's Tobacco Plan Excludes 6-Methyl Nicotine as Customs Tightens Import Controls and Analog Liquid Imports Fall 83%
South Korea's government unveiled its first Tobacco Harm Management Basic Plan for 2027–2031 on October 29, 2026, proposing broader testing of vaping and heated tobacco products while excluding nicotine analogs such as 6-methyl nicotine. Synthetic nicotine came under tobacco regulation on April 24, and a June investigation found 6-methyl nicotine in 12 liquid inhalation products marketed as nicotine-free. Customs data released in September showed that imports of nicotine analog solutions fell 83.3%, from 12 metric tons in January–April to 2 metric tons in May–August. By September 20, imports had reached approximately 15 metric tons for the year, with 99.99% originating from China. Customs authorities have tightened pre-clearance testing and supply-chain documentation requirements, while the MFDS expects to complete its assessment of nicotine analog hazards by the end of 2026.
Regulations
Nov.04